Pub Date : 2023-04-24eCollection Date: 2023-12-01DOI: 10.1016/j.ajmo.2023.100042
Jessica Castrillon Lal, Luba Margai, Helen Sarah Zitkovsky, Lori Lyn Price, Shirley González
Objective: Obesity affects 14.7 million children and adolescents in the United States. Children's health behaviors are affected by parental health practices. Therefore, pediatric obesity interventions should include parents. The objective of this study was to assess the changes in self-reported health behaviors in a diverse population attending the TEEEN program, with motivational interviewing of child-parent dyads as a key component, for 1 year.
Methods: Here we assessed the changes in Family and Nutrition and Physical Activity (FNPA) screening tool scores, a tool that assesses obesogenic behaviors, in the context of MI of child-parent dyads in a racially, ethnically, and socioeconomically diverse population who attended the TEEEN (Teens, Empowerment, Education, Exercise, Nutrition) program, a nonclinic and family-based behavior program in Massachusetts, for 1 year.
Results: Participation in the TEEEN program, which includes MI of child-parent dyads, was associated with a significant increase in the overall FNPA score (median change= 4 points, P = .007). We observed that 76.5% of children experienced a decrease in BMI% and BMI z-score. The change in BMI% (median= -0.9, P = .006) and change in BMI z-score (median= -0.2, P = .008) were statistically significant.
Conclusion: Participation in the TEEEN program seemed to be beneficial based on aspects of the FNPA screening tool and changes in weight parameters. The FNPA screening tool enhanced-motivational interviewing of child-parent dyads shows promise as an approach to address obesogenic behaviors. This study provides a detailed framework for medical providers to address pediatric obesity in a nonclinic setting with less time constraints.
{"title":"Improving Health Behaviors and Weight Parameters With Motivational Interviewing and the TEEEN Program in an Ethnically and Socioeconomically Diverse Pediatric Population.","authors":"Jessica Castrillon Lal, Luba Margai, Helen Sarah Zitkovsky, Lori Lyn Price, Shirley González","doi":"10.1016/j.ajmo.2023.100042","DOIUrl":"10.1016/j.ajmo.2023.100042","url":null,"abstract":"<p><strong>Objective: </strong>Obesity affects 14.7 million children and adolescents in the United States. Children's health behaviors are affected by parental health practices. Therefore, pediatric obesity interventions should include parents. The objective of this study was to assess the changes in self-reported health behaviors in a diverse population attending the TEEEN program, with motivational interviewing of child-parent dyads as a key component, for 1 year.</p><p><strong>Methods: </strong>Here we assessed the changes in Family and Nutrition and Physical Activity (FNPA) screening tool scores, a tool that assesses obesogenic behaviors, in the context of MI of child-parent dyads in a racially, ethnically, and socioeconomically diverse population who attended the TEEEN (Teens, Empowerment, Education, Exercise, Nutrition) program, a nonclinic and family-based behavior program in Massachusetts, for 1 year.</p><p><strong>Results: </strong>Participation in the TEEEN program, which includes MI of child-parent dyads, was associated with a significant increase in the overall FNPA score (median change= 4 points, <i>P</i> = .007). We observed that 76.5% of children experienced a decrease in BMI% and BMI z-score. The change in BMI% (median= -0.9, <i>P</i> = .006) and change in BMI z-score (median= -0.2, <i>P</i> = .008) were statistically significant.</p><p><strong>Conclusion: </strong>Participation in the TEEEN program seemed to be beneficial based on aspects of the FNPA screening tool and changes in weight parameters. The FNPA screening tool enhanced-motivational interviewing of child-parent dyads shows promise as an approach to address obesogenic behaviors. This study provides a detailed framework for medical providers to address pediatric obesity in a nonclinic setting with less time constraints.</p>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":" ","pages":"100042"},"PeriodicalIF":0.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42373709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-24DOI: 10.1016/j.ajmo.2023.100042
Jessica Castrillon Lal , Luba Margai , Helen Sarah Zitkovsky , Lori Lyn Price , Shirley González , American Board of Obesity Medicine Diplomate
Objective
Obesity affects 14.7 million children and adolescents in the United States. Children's health behaviors are affected by parental health practices. Therefore, pediatric obesity interventions should include parents. The objective of this study was to assess the changes in self-reported health behaviors in a diverse population attending the TEEEN program, with motivational interviewing of child-parent dyads as a key component, for 1 year.
Methods
Here we assessed the changes in Family and Nutrition and Physical Activity (FNPA) screening tool scores, a tool that assesses obesogenic behaviors, in the context of MI of child-parent dyads in a racially, ethnically, and socioeconomically diverse population who attended the TEEEN (Teens, Empowerment, Education, Exercise, Nutrition) program, a nonclinic and family-based behavior program in Massachusetts, for 1 year.
Results
Participation in the TEEEN program, which includes MI of child-parent dyads, was associated with a significant increase in the overall FNPA score (median change= 4 points, P = .007). We observed that 76.5% of children experienced a decrease in BMI% and BMI z-score. The change in BMI% (median= −0.9, P = .006) and change in BMI z-score (median= −0.2, P = .008) were statistically significant.
Conclusion
Participation in the TEEEN program seemed to be beneficial based on aspects of the FNPA screening tool and changes in weight parameters. The FNPA screening tool enhanced-motivational interviewing of child-parent dyads shows promise as an approach to address obesogenic behaviors. This study provides a detailed framework for medical providers to address pediatric obesity in a nonclinic setting with less time constraints.
{"title":"Improving Health Behaviors and Weight Parameters With Motivational Interviewing and the TEEEN Program in an Ethnically and Socioeconomically Diverse Pediatric Population","authors":"Jessica Castrillon Lal , Luba Margai , Helen Sarah Zitkovsky , Lori Lyn Price , Shirley González , American Board of Obesity Medicine Diplomate","doi":"10.1016/j.ajmo.2023.100042","DOIUrl":"https://doi.org/10.1016/j.ajmo.2023.100042","url":null,"abstract":"<div><h3>Objective</h3><p>Obesity affects 14.7 million children and adolescents in the United States. Children's health behaviors are affected by parental health practices. Therefore, pediatric obesity interventions should include parents. The objective of this study was to assess the changes in self-reported health behaviors in a diverse population attending the TEEEN program, with motivational interviewing of child-parent dyads as a key component, for 1 year.</p></div><div><h3>Methods</h3><p>Here we assessed the changes in Family and Nutrition and Physical Activity (FNPA) screening tool scores, a tool that assesses obesogenic behaviors, in the context of MI of child-parent dyads in a racially, ethnically, and socioeconomically diverse population who attended the TEEEN (Teens, Empowerment, Education, Exercise, Nutrition) program, a nonclinic and family-based behavior program in Massachusetts, for 1 year.</p></div><div><h3>Results</h3><p>Participation in the TEEEN program, which includes MI of child-parent dyads, was associated with a significant increase in the overall FNPA score (median change= 4 points, <em>P</em> = .007). We observed that 76.5% of children experienced a decrease in BMI% and BMI z-score. The change in BMI% (median= −0.9, <em>P</em> = .006) and change in BMI z-score (median= −0.2, <em>P</em> = .008) were statistically significant.</p></div><div><h3>Conclusion</h3><p>Participation in the TEEEN program seemed to be beneficial based on aspects of the FNPA screening tool and changes in weight parameters. The FNPA screening tool enhanced-motivational interviewing of child-parent dyads shows promise as an approach to address obesogenic behaviors. This study provides a detailed framework for medical providers to address pediatric obesity in a nonclinic setting with less time constraints.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"10 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49734707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-25DOI: 10.1016/j.ajmo.2023.100038
Yaa Ababio , Scott P. Kelly , Franca S Angeli , Joanne Berghout , Kui Huang , Kathy Liu , Sara Burns , Cynthia Senerchia , Rob Moccia , Gabriel C. Brooks
Background
Dilated cardiomyopathy (DCM) contributes significantly to heart failure prevalence, yet supporting epidemiologic data is sparse. This study sought to estimate the period prevalence of DCM and the proportion of idiopathic DCM in the United States using a large, diverse electronic health records (EHR) database.
Methods
This retrospective, observational study included 56,812,806 deidentified patients in Optum EHR with visits between 2017 and 2019. Suspected DCM cases were identified using ICD-10 coding. Deidentified clinical notes from 1000 randomly selected cases were manually reviewed to determine the diagnosis of DCM and estimate the proportion of idiopathic DCM. The period prevalence and clinical burden of DCM and idiopathic DCM were estimated.
Results
Manual clinical review demonstrated that our definition had a positive predictive value of 92.5% for DCM, with 46.3% estimated as the idiopathic DCM proportion. The estimated period prevalence of DCM between 2017 and 2019 was 118.33 per 100,000. Prevalence increased for adults ≥65 years of age, males, and African Americans. Extrapolation to the 2019 US population led to an overall estimated burden of roughly 388,350 patients. Adjusting for the proportion of cases with idiopathic DCM yielded an idiopathic DCM prevalence of 59.23 per 100,000 and a burden of 194,385 patients. Evidence of clinical genetic testing in this population was scarce, with less than 0.43% of DCM cases reporting a testing code.
Conclusions
This study establishes a conservative period prevalence for DCM and idiopathic DCM and demonstrates very low molecular genetic testing for DCM. These findings suggest that the clinical burden of genetic DCM may be underestimated.
{"title":"Prevalence and Clinical Burden of Idiopathic Dilated Cardiomyopathy in the United States","authors":"Yaa Ababio , Scott P. Kelly , Franca S Angeli , Joanne Berghout , Kui Huang , Kathy Liu , Sara Burns , Cynthia Senerchia , Rob Moccia , Gabriel C. Brooks","doi":"10.1016/j.ajmo.2023.100038","DOIUrl":"https://doi.org/10.1016/j.ajmo.2023.100038","url":null,"abstract":"<div><h3>Background</h3><p>Dilated cardiomyopathy (DCM) contributes significantly to heart failure prevalence, yet supporting epidemiologic data is sparse. This study sought to estimate the period prevalence of DCM and the proportion of idiopathic DCM in the United States using a large, diverse electronic health records (EHR) database.</p></div><div><h3>Methods</h3><p>This retrospective, observational study included 56,812,806 deidentified patients in Optum EHR with visits between 2017 and 2019. Suspected DCM cases were identified using ICD-10 coding. Deidentified clinical notes from 1000 randomly selected cases were manually reviewed to determine the diagnosis of DCM and estimate the proportion of idiopathic DCM. The period prevalence and clinical burden of DCM and idiopathic DCM were estimated.</p></div><div><h3>Results</h3><p>Manual clinical review demonstrated that our definition had a positive predictive value of 92.5% for DCM, with 46.3% estimated as the idiopathic DCM proportion. The estimated period prevalence of DCM between 2017 and 2019 was 118.33 per 100,000. Prevalence increased for adults ≥65 years of age, males, and African Americans. Extrapolation to the 2019 US population led to an overall estimated burden of roughly 388,350 patients. Adjusting for the proportion of cases with idiopathic DCM yielded an idiopathic DCM prevalence of 59.23 per 100,000 and a burden of 194,385 patients. Evidence of clinical genetic testing in this population was scarce, with less than 0.43% of DCM cases reporting a testing code.</p></div><div><h3>Conclusions</h3><p>This study establishes a conservative period prevalence for DCM and idiopathic DCM and demonstrates very low molecular genetic testing for DCM. These findings suggest that the clinical burden of genetic DCM may be underestimated.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"10 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49734708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-18eCollection Date: 2023-06-01DOI: 10.1016/j.ajmo.2023.100035
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A Glassman, Sherrie L Aspinall
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing. The objective was to evaluate clinical effectiveness and safety of PCSK9-Is within the Veterans Health Administration (VHA).
Methods: In this retrospective cohort study, we included Veterans who had at least one outpatient prescription for alirocumab and/or evolocumab filled within VHA between August 21, 2015, and September 30, 2020. Analyses included 4 mutually exclusive subgroups: PCSK9-I alone, PCSK9-I+statin, PCSK9-I+ezetimibe, and PCSK9-I+statin+ezetimibe subgroups. Primary outcomes included medication possession ratio, persistence, and low-density lipoprotein (LDL).
Results: Among Veterans in the analytical cohort (n = 2428), 36.2% were on PCSK9-I monotherapy; 24.0% received a PCSK9-I+statin; 27.4% were on a PCSK9-I+ezetimibe; and 12.4% received triple therapy, that is, PCSK9-I+statin+ezetimibe. The mean medication possession ratio (standard deviation [SD]) for PCSK9-I monotherapy was 83.8% (13.3) compared to 84.3% (11.2) with PCSK9-I+statin therapy, 87.1% (10.1) with PCSK9-I+ezetimibe therapy, and 85.8% (11.7) with triple therapy. The percentage of patients who discontinued PCSK9-I in the monotherapy subgroup was 12.3% vs 9.5%, 6.6%, and 7.4% in the concomitant statin, ezetimibe, and triple-therapy subgroups, respectively (p = .002 among the groups). Mean LDL level was greater in the PCSK9-I monotherapy subgroup (85.6 mg/dL) compared with the concomitant statin (66.5 mg/dL), ezetimibe (65.7 mg/dL), and triple-therapy subgroups (68.1 mg/dL).
Conclusions: Veterans showed good adherence and/or persistence with PCSK9-I regimens. On average, those receiving concomitant therapy with a statin and/or ezetimibe achieved significantly lower LDL levels.
{"title":"PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration.","authors":"Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A Glassman, Sherrie L Aspinall","doi":"10.1016/j.ajmo.2023.100035","DOIUrl":"10.1016/j.ajmo.2023.100035","url":null,"abstract":"<p><strong>Background: </strong>Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing. The objective was to evaluate clinical effectiveness and safety of PCSK9-Is within the Veterans Health Administration (VHA).</p><p><strong>Methods: </strong>In this retrospective cohort study, we included Veterans who had at least one outpatient prescription for alirocumab and/or evolocumab filled within VHA between August 21, 2015, and September 30, 2020. Analyses included 4 mutually exclusive subgroups: PCSK9-I alone, PCSK9-I+statin, PCSK9-I+ezetimibe, and PCSK9-I+statin+ezetimibe subgroups. Primary outcomes included medication possession ratio, persistence, and low-density lipoprotein (LDL).</p><p><strong>Results: </strong>Among Veterans in the analytical cohort (<i>n</i> = 2428), 36.2% were on PCSK9-I monotherapy; 24.0% received a PCSK9-I+statin; 27.4% were on a PCSK9-I+ezetimibe; and 12.4% received triple therapy, that is, PCSK9-I+statin+ezetimibe. The mean medication possession ratio (standard deviation [SD]) for PCSK9-I monotherapy was 83.8% (13.3) compared to 84.3% (11.2) with PCSK9-I+statin therapy, 87.1% (10.1) with PCSK9-I+ezetimibe therapy, and 85.8% (11.7) with triple therapy. The percentage of patients who discontinued PCSK9-I in the monotherapy subgroup was 12.3% vs 9.5%, 6.6%, and 7.4% in the concomitant statin, ezetimibe, and triple-therapy subgroups, respectively (<i>p</i> = .002 among the groups). Mean LDL level was greater in the PCSK9-I monotherapy subgroup (85.6 mg/dL) compared with the concomitant statin (66.5 mg/dL), ezetimibe (65.7 mg/dL), and triple-therapy subgroups (68.1 mg/dL).</p><p><strong>Conclusions: </strong>Veterans showed good adherence and/or persistence with PCSK9-I regimens. On average, those receiving concomitant therapy with a statin and/or ezetimibe achieved significantly lower LDL levels.</p>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":" ","pages":"100035"},"PeriodicalIF":0.0,"publicationDate":"2023-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49482490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100018
Dayawa D. Agoons , Batakeh B. Agoons , Kelechi E. Emmanuel , Firdausi A. Matawalle , Jessica M. Cunningham
{"title":"Author's response","authors":"Dayawa D. Agoons , Batakeh B. Agoons , Kelechi E. Emmanuel , Firdausi A. Matawalle , Jessica M. Cunningham","doi":"10.1016/j.ajmo.2022.100018","DOIUrl":"https://doi.org/10.1016/j.ajmo.2022.100018","url":null,"abstract":"","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100018"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667036422000127/pdfft?md5=b99c07c227a3565a3e8b2131e88fcf3f&pid=1-s2.0-S2667036422000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136884685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100024
Sophie Ziai , Florian Naudet , Bruno Laviolle , Jean-Sébastien Allain
Introduction
Under-representation of women in high academic and medical positions is reported in many countries. This study aims to compare degrees and careers between men and women tenured as Full Professors of Medicine in recent years in France.
Methods
We identified all new tenured French Full Professors between 2017 and 2021 and collected the publicly available data (gender, year of birth, curriculum) from the Bibliographic Agency for Higher Education, a public institution under the aegis of the Ministry for Higher Education Research and Innovation. The primary outcome was the gender difference in age appointment of Full Professors. Secondary outcomes were gender differences in career development.
Results
Among 820 Full Professors, only 266 (32.4%) were women. They were tenured at a later age than men (43.7 vs 42.4 years, p<0.001), while they graduated for the MD (29.5 vs 29.9 years, p<0.005) or PhD (35.3 vs 36.0 years, p<0.05) several months earlier. Women were also more often Associate Professors than men before becoming Full Professors (67.3% vs 59.2%, p<0.05). Before achieving Full professor tenure, the average delay is longer for women from MD graduation (14.6 vs 12.5 years), PhD graduation (8.7 vs 6.4 years), or Associate Professor nomination (7.5 vs 5.5 years), with a difference of 2.2, 2.4 and 2.0 years respectively (p<0.001 for all comparisons).
Conclusion
Gender inequalities remain in regards to access to Full Professor status, the highest position in the medical fields.
导言据报道,在许多国家,妇女在高级学术和医疗职位上的代表性不足。这项研究旨在比较近年来法国男性和女性医学全职教授的学位和职业。方法:我们确定了2017年至2021年间所有新的法国终身教授,并从高等教育文献局(高等教育研究与创新部下属的公共机构)收集了公开可用的数据(性别、出生年份、课程)。主要结果是全职教授在年龄上的性别差异。次要结果是职业发展的性别差异。结果在820名正教授中,女性只有266人(32.4%)。她们获得终身职位的年龄比男性晚(43.7年对42.4年,p < 0.001),而她们获得医学博士学位(29.5年对29.9年,p < 0.001)或博士学位(35.3年对36.0年,p < 0.05)的时间比男性早几个月。在成为正教授之前,女性也比男性更多地成为副教授(67.3% vs 59.2%, p<0.05)。在获得正教授任期之前,女性从医学博士毕业(14.6年对12.5年)、博士毕业(8.7年对6.4年)或副教授提名(7.5年对5.5年)获得职位的平均延迟时间更长,差异分别为2.2年、2.4年和2.0年(所有比较的差异为0.001)。结论在获得医学领域最高职位——正教授地位方面,性别不平等现象仍然存在。
{"title":"Gender inequality for tenure as Full Professor of medicine in France","authors":"Sophie Ziai , Florian Naudet , Bruno Laviolle , Jean-Sébastien Allain","doi":"10.1016/j.ajmo.2022.100024","DOIUrl":"10.1016/j.ajmo.2022.100024","url":null,"abstract":"<div><h3>Introduction</h3><p>Under-representation of women in high academic and medical positions is reported in many countries. This study aims to compare degrees and careers between men and women tenured as Full Professors of Medicine in recent years in France.</p></div><div><h3>Methods</h3><p>We identified all new tenured French Full Professors between 2017 and 2021 and collected the publicly available data (gender, year of birth, curriculum) from the Bibliographic Agency for Higher Education, a public institution under the aegis of the Ministry for Higher Education Research and Innovation. The primary outcome was the gender difference in age appointment of Full Professors. Secondary outcomes were gender differences in career development.</p></div><div><h3>Results</h3><p>Among 820 Full Professors, only 266 (32.4%) were women. They were tenured at a later age than men (43.7 vs 42.4 years, p<0.001), while they graduated for the MD (29.5 vs 29.9 years, p<0.005) or PhD (35.3 vs 36.0 years, p<0.05) several months earlier. Women were also more often Associate Professors than men before becoming Full Professors (67.3% vs 59.2%, p<0.05). Before achieving Full professor tenure, the average delay is longer for women from MD graduation (14.6 vs 12.5 years), PhD graduation (8.7 vs 6.4 years), or Associate Professor nomination (7.5 vs 5.5 years), with a difference of 2.2, 2.4 and 2.0 years respectively (p<0.001 for all comparisons).</p></div><div><h3>Conclusion</h3><p>Gender inequalities remain in regards to access to Full Professor status, the highest position in the medical fields.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100024"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703642200019X/pdfft?md5=d8e476e2f836219434afcda66baf572c&pid=1-s2.0-S266703642200019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45007099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100015
Leslie C.M. Johnson , Nancy J. Thompson , Mohammed K. Ali , Kirk Elifson , Lydia Chwastiak , Viswanathan Mohan , Ranjit Mohan Anjana , Subramani Poongothai , Nikhil Tandon
Aims
We aimed to determine what key resources, mechanisms, and contextual factors are necessary to integrate depression and diabetes treatment into low-resource settings.
Methods
A realist evaluation framework was employed to conduct a comparative case study. Data were collected through document review, key informant interviews (n=4), activity logs, and interviews with implementing health care providers (n=11) to test and refine program theories for collaborative care.
Results
Efforts to enhance patient care coordination (i.e., adapting clinics’ patient flow and resources, on-going trainings, and on-site support for care coordinators) improved implementation of depression treatment by usual care diabetes physicians. Clinician's avoidance of the term depression was identified as a barrier to mental health counseling and treatment.
Conclusions
The variations in organizational features and processes linked to implementation activities across two clinics provided an opportunity to examine how and why different contextual factors help or hinder the implementation process. Findings from this study demonstrate that successful implementation of an integrated depression and diabetes care model is feasible in a low-resource setting, while the revised program theories provide an explanatory framework of coordinated care implementation processes that can inform future efforts to disseminate and scale this care model.
{"title":"A realist process evaluation of the INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) randomized controlled trial in India","authors":"Leslie C.M. Johnson , Nancy J. Thompson , Mohammed K. Ali , Kirk Elifson , Lydia Chwastiak , Viswanathan Mohan , Ranjit Mohan Anjana , Subramani Poongothai , Nikhil Tandon","doi":"10.1016/j.ajmo.2022.100015","DOIUrl":"10.1016/j.ajmo.2022.100015","url":null,"abstract":"<div><h3>Aims</h3><p>We aimed to determine what key resources, mechanisms, and contextual factors are necessary to integrate depression and diabetes treatment into low-resource settings.</p></div><div><h3>Methods</h3><p>A realist evaluation framework was employed to conduct a comparative case study. Data were collected through document review, key informant interviews (<em>n</em>=4), activity logs, and interviews with implementing health care providers (n=11) to test and refine program theories for collaborative care.</p></div><div><h3>Results</h3><p>Efforts to enhance patient care coordination (i.e., adapting clinics’ patient flow and resources, on-going trainings, and on-site support for care coordinators) improved implementation of depression treatment by usual care diabetes physicians. Clinician's avoidance of the term depression was identified as a barrier to mental health counseling and treatment.</p></div><div><h3>Conclusions</h3><p>The variations in organizational features and processes linked to implementation activities across two clinics provided an opportunity to examine how and why different contextual factors help or hinder the implementation process. Findings from this study demonstrate that successful implementation of an integrated depression and diabetes care model is feasible in a low-resource setting, while the revised program theories provide an explanatory framework of coordinated care implementation processes that can inform future efforts to disseminate and scale this care model.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100015"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/f0/nihms-1858340.PMC9788650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10506006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100027
Herman Joseph Johannesmeyer , Kayvan Moussavi , Kerry Anne Rambaran , Kristica Kolyouthapong
Background
While international guidelines recommend low doses of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) clinical practice patterns show significant heterogeneity. Increasing doses of corticosteroids have inconsistently been associated with a greater risk of hyperglycemia.
Methods
Patients admitted to inpatient services for AECOPD were retrospectively enrolled. Hospitalization corticosteroid doses, daily blood glucose levels, and other markers of corticosteroid excess were collected. Correlative and regression analyses were conducted to assess the relationship between corticosteroid dose and average hospitalization blood glucose.
Results
Daily corticosteroid dose significantly predicted a higher blood glucose (rs=0.179, p=0.0095; p<0.0028 respectively) and cumulative corticosteroid dose predicted a longer hospital length of stay in bivariate and multivariate analyses (rs=0.679, p<0.0001; p<0.0001 respectively). Patients that experienced hypernatremia, hypokalemia, acute hyperglycemia, and acute hypertension received larger corticosteroid doses than patients that did not experience these complicating events.
Conclusions
We identified that increasing amounts of corticosteroids administered to inpatients experiencing AECOPD experienced higher average hospitalization blood glucose values, protracted hospitalizations, and other untoward effects.
{"title":"Corticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease","authors":"Herman Joseph Johannesmeyer , Kayvan Moussavi , Kerry Anne Rambaran , Kristica Kolyouthapong","doi":"10.1016/j.ajmo.2022.100027","DOIUrl":"10.1016/j.ajmo.2022.100027","url":null,"abstract":"<div><h3>Background</h3><p>While international guidelines recommend low doses of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) clinical practice patterns show significant heterogeneity. Increasing doses of corticosteroids have inconsistently been associated with a greater risk of hyperglycemia.</p></div><div><h3>Methods</h3><p>Patients admitted to inpatient services for AECOPD were retrospectively enrolled. Hospitalization corticosteroid doses, daily blood glucose levels, and other markers of corticosteroid excess were collected. Correlative and regression analyses were conducted to assess the relationship between corticosteroid dose and average hospitalization blood glucose.</p></div><div><h3>Results</h3><p>Daily corticosteroid dose significantly predicted a higher blood glucose (rs=0.179, p=0.0095; p<0.0028 respectively) and cumulative corticosteroid dose predicted a longer hospital length of stay in bivariate and multivariate analyses (rs=0.679, p<0.0001; p<0.0001 respectively). Patients that experienced hypernatremia, hypokalemia, acute hyperglycemia, and acute hypertension received larger corticosteroid doses than patients that did not experience these complicating events.</p></div><div><h3>Conclusions</h3><p>We identified that increasing amounts of corticosteroids administered to inpatients experiencing AECOPD experienced higher average hospitalization blood glucose values, protracted hospitalizations, and other untoward effects.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100027"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703642200022X/pdfft?md5=641ab8f5fbbe02e6d7309c7b3fa65326&pid=1-s2.0-S266703642200022X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46002353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100009
Gisela Büchele , Martin Rehm , Rebecca Halbgebauer , Dietrich Rothenbacher , Markus Huber-Lang
Objectives: Although femoral fractures can hit anyone, they carry an especially high burden in the elderly and are multifaceted in their injury pattern, related complications, and subsequent therapeutic strategies. An often underestimated posttraumatic risk is the development of trauma-related acute kidney injury (TRAKI). However, for TRAKI, no outcome study with a large data approach exists addressing fractures. Therefore, we analyzed the development of TRAKI in regard to different covariates and quantified the association of TRAKI with overall mortality.
Design: Retrospective cohort study with claims data.
Setting and participants: 119,000 patients from Germany with femur fracture.
Methods: We calculated cumulative mortality, mortality rates per 100 person-years (both occurring within 180 days after fracture), and adjusted hazard ratios with 95%-confidence intervals (CI).
Results: Patients with femur shaft fractures showed an incidence of 6.1% for TRAKI, followed by patients with femur neck fractures with an incidence of 5.7%, and by patients with distal fractures with an incidence of 4.5%, respectively. Overall, in patients with any femur fracture, we found a 3.17-times higher mortality rate (95%-CI: 3.02-3.26) during 180 days of observation in patients who developed TRAKI in comparison to patients without. The risk for development of TRAKI was significantly increased with increasing TRAKI stage, age, and time until surgical intervention.
Conclusions and implications: In conclusion, patients suffering from proximal-, shaft-, and distal femoral fracture face an over 3-times higher 180 day-mortality rate in case of posttraumatic TRAKI, which should be considered in peri-traumatic care to improve the long-term outcome of these patients.
{"title":"Trauma-related acute kidney injury during inpatient care of femoral fractures increases the risk of mortality: A claims data analysis","authors":"Gisela Büchele , Martin Rehm , Rebecca Halbgebauer , Dietrich Rothenbacher , Markus Huber-Lang","doi":"10.1016/j.ajmo.2022.100009","DOIUrl":"10.1016/j.ajmo.2022.100009","url":null,"abstract":"<div><p><em>Objectives:</em> Although femoral fractures can hit anyone, they carry an especially high burden in the elderly and are multifaceted in their injury pattern, related complications, and subsequent therapeutic strategies. An often underestimated posttraumatic risk is the development of trauma-related acute kidney injury (TRAKI). However, for TRAKI, no outcome study with a large data approach exists addressing fractures. Therefore, we analyzed the development of TRAKI in regard to different covariates and quantified the association of TRAKI with overall mortality.</p><p><em>Design:</em> Retrospective cohort study with claims data.</p><p><em>Setting and participants:</em> 119,000 patients from Germany with femur fracture.</p><p><em>Methods:</em> We calculated cumulative mortality, mortality rates per 100 person-years (both occurring within 180 days after fracture), and adjusted hazard ratios with 95%-confidence intervals (CI).</p><p><em>Results:</em> Patients with femur shaft fractures showed an incidence of 6.1% for TRAKI, followed by patients with femur neck fractures with an incidence of 5.7%, and by patients with distal fractures with an incidence of 4.5%, respectively. Overall, in patients with any femur fracture, we found a 3.17-times higher mortality rate (95%-CI: 3.02-3.26) during 180 days of observation in patients who developed TRAKI in comparison to patients without. The risk for development of TRAKI was significantly increased with increasing TRAKI stage, age, and time until surgical intervention.</p><p><em>Conclusions and implications:</em> In conclusion, patients suffering from proximal-, shaft-, and distal femoral fracture face an over 3-times higher 180 day-mortality rate in case of posttraumatic TRAKI, which should be considered in peri-traumatic care to improve the long-term outcome of these patients.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100009"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667036422000048/pdfft?md5=d0da7aa8145eec79a6caf108bfbdc864&pid=1-s2.0-S2667036422000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45733828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1016/j.ajmo.2022.100022
Ramya Radhakrishnan, William Cade, Ernesto Bernal-Mizrachi, Rajesh Garg
Objective
This study was conducted to evaluate whether the type of insurance coverage is associated with missed appointments and to evaluate the effect of missed appointments on diabetes control.
Methods
All patients with diabetes mellitus (DM) managed at a major academic medical center between Jan 2015 and Dec 2020 were included in analysis. Association between insurance coverage and the proportion of missed appointments was evaluated with adjustments for demographic variables and social determinants of health. The relationship between proportion of missed appointments and glycemic control was also evaluated.
Results
The dataset included 30,633 patients, out of which 14,064 (46%) reported commercial insurance, 13,376 (44%) reported Medicare and 3,193 (10%) reported Medicaid coverage. Proportion of missed appointments was 18.1 ± 18.1% among Medicaid covered patients,12.1 ± 15.3% among commercially insured and 10.2 ± 14.1% among Medicare covered patients (p < 0.001). Type of insurance was found to be a significant predictor of proportion of missed appointments after adjusting for age, race, language, marital status, smoking, BMI, HbA1c and type of diabetes (p < 0.001) in series regression analysis. Proportion of missed appointments was associated with HbA1c with partial correlation coefficient +0.104 (p < 0.005) after adjusting for age, race, gender, type of insurance coverage, BMI and type of diabetes.
Conclusions
Medicaid covered patients with diabetes have higher proportion of missed clinic appointments and higher HbA1c. More research is needed to evaluate the root causes of inability to keep appointments in this population so that strategies for improved healthcare delivery can be designed.
{"title":"Medicaid insured persons with diabetes have increased proportion of missed appointments and high HbA1c","authors":"Ramya Radhakrishnan, William Cade, Ernesto Bernal-Mizrachi, Rajesh Garg","doi":"10.1016/j.ajmo.2022.100022","DOIUrl":"https://doi.org/10.1016/j.ajmo.2022.100022","url":null,"abstract":"<div><h3>Objective</h3><p>This study was conducted to evaluate whether the type of insurance coverage is associated with missed appointments and to evaluate the effect of missed appointments on diabetes control.</p></div><div><h3>Methods</h3><p>All patients with diabetes mellitus (DM) managed at a major academic medical center between Jan 2015 and Dec 2020 were included in analysis. Association between insurance coverage and the proportion of missed appointments was evaluated with adjustments for demographic variables and social determinants of health. The relationship between proportion of missed appointments and glycemic control was also evaluated.</p></div><div><h3>Results</h3><p>The dataset included 30,633 patients, out of which 14,064 (46%) reported commercial insurance, 13,376 (44%) reported Medicare and 3,193 (10%) reported Medicaid coverage. Proportion of missed appointments was 18.1 ± 18.1% among Medicaid covered patients,12.1 ± 15.3% among commercially insured and 10.2 ± 14.1% among Medicare covered patients (<em>p</em> < 0.001). Type of insurance was found to be a significant predictor of proportion of missed appointments after adjusting for age, race, language, marital status, smoking, BMI, HbA1c and type of diabetes (<em>p</em> < 0.001) in series regression analysis. Proportion of missed appointments was associated with HbA1c with partial correlation coefficient +0.104 (<em>p</em> < 0.005) after adjusting for age, race, gender, type of insurance coverage, BMI and type of diabetes.</p></div><div><h3>Conclusions</h3><p>Medicaid covered patients with diabetes have higher proportion of missed clinic appointments and higher HbA1c. More research is needed to evaluate the root causes of inability to keep appointments in this population so that strategies for improved healthcare delivery can be designed.</p></div>","PeriodicalId":72168,"journal":{"name":"American journal of medicine open","volume":"8 ","pages":"Article 100022"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667036422000176/pdfft?md5=29838a781a5056f0325313cef8d2fc2a&pid=1-s2.0-S2667036422000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136885551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}